Efficacy of Topical Glucosamine Versus Corticosteroid in Oral Lichen Planus
Key facts
- Who runs it
- Future University in Egypt
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 36 people enrolled
- Started
- 1 May 2023
- Ended
- 31 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Glucosamine Hydrochloride
- Triamcinolone Acetonide
- Record updated
- 17 August 2025
Who can take part
- Age
- 25 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Clinically proven painful bullous/erosive or atrophic forms of OLP
- Histopathologically proven bullous/erosive or atrophic forms of OLP
Who cannot take part
- History of previous treatments potentially effective on OLP
- Presence of systemic conditions
- Hypersensitivity or severe adverse effects to the treatment drugs or to any ingredient of their preparation as mentioned in medical history
- Lichenoid lesions
- Smoking
- Pregnancy or breast-feeding
- Presence of skin lesions
- Loss of pliability or flexibility in the tissues involved by the oral lesions of lichen planus
- Histological signs of epithelial dysplasia or lichenoid lesions within the biopsied sites
- Refusing to participate in the study
- Vulnerable groups
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan. It is classified as a nutraceutical and it is used mainly orally for the therapy of osteoarthritis since GlcN has immunoregulatory capacity and anti-inflammatory effects. Given the Oral lichen planus (OLP) T-cell-mediated pathogenesis; this drug seems to be a promising therapeutic option. The investigators compared the clinical efficacy of topical glucosamine to topical corticosteroid in the treatment of symptomatic OLP and investigated the effect of these two treatment modalities on the expression of tumor necrosis factor-alpha (TNF-α) in oral lichen planus lesions
The 2 groups in the trial
- GlucosamineTreatment being tested
(Topical glucosamine hydrochloride 1%) Four times per day for 8 weeks
Treatment: Glucosamine Hydrochloride
- CorticosteroidsExisting treatment, for comparison
Topical steroid (triamcinolone acetonide 0.1 %) four times per day for 8 weeks
Treatment: Triamcinolone Acetonide
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Efficacy of Topical Glucosamine Versus Corticosteroid on Tumor Necrosis Factor -Alpha Induced Apoptosis in Oral Lichen Planus: A Randomized Controlled Clinical Trial With Immunohistochemical Analysis
- Record updated
- 17 August 2025